Randomized clinical trials such as CREDENCE [52]—(Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) and DAPA-CKD [53, 54] (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) evaluated sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with T2DM and DKD, proving the reduction of renal outcomes, such as progression to advanced kidney disease, the need for dialysis and renal death. Here, SLC5A2 is linked to chronic kidney disease.